Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • 25 MAY 16

    Spring Bank Pharmaceuticals to Present at Upcoming Investor Conferences

    MILFORD, Mass., May 25, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that the Company will present at the following upcoming investor conferences:

    The Marcum MicroCap Conference on Thursday, June 2, 2016, at 2:30 pm Eastern Time at the Grand Hyatt in New York City
     
    The JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 10:30 am Eastern Time at The St. Regis in New York City

    Live audio webcasts of the presentations will be available on the company’s website at http://ir.springbankpharm.com. Replays of the…

    Read more →
    • 11 MAY 16

    Spring Bank Pharmaceuticals Announces Closing of Initial Public Offering

    MILFORD, Mass., May 11, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the closing of its initial public offering of 920,000 shares of common stock at a public offering price of $12.00 per share, resulting in gross proceeds of approximately $11 million, before underwriting discounts and commissions and offering-related expenses. All of the shares in the offering were sold by Spring Bank.  In addition, Spring Bank has granted the underwriters a 30-day option to purchase from the company, at the public offering price, less underwriting dis…

    Read more →